BIOGEN INC. is 13.8x more valuable than BIOCRYST PHARMACEUTICALS INC by market capitalization ($28.68 B vs $2.08 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BCRX | BIIB |
|---|---|---|
| Market cap | $2.08 B | $28.68 B |
| US-listed rank | #2072 | #476 |
| Revenue (latest FY) | $25.19M | $9.89B |
| Net income (latest FY) | $263.86M | $1.29B |
| Net margin | 1047.6% | 13.1% |
| P/E (trailing FY) | 7.9 | 22.2 |
| SEC filings | 1,935 | 2,690 |
BIOGEN INC. is 13.8x more valuable than BIOCRYST PHARMACEUTICALS INC by market capitalization ($28.68 B vs $2.08 B).
In their latest fiscal years, BIOCRYST PHARMACEUTICALS INC reported $25.19M in revenue while BIOGEN INC. reported $9.89B.
Full pages: BIOCRYST PHARMACEUTICALS INC and BIOGEN INC., or browse the full rankings.